• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Silo Pharma, Inc. - Common Stock (NQ:SILO)

    1.980 -0.090 (-4.35%)
    Streaming Delayed Price Updated: 10:24 AM EDT, Sep 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Silo Pharma, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    News headline image
    Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying ↗
    The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
    Via Benzinga
    Topics Stocks
    News headline image
    Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More ↗
     
    Via Benzinga
    News headline image
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗
     
    Via Benzinga
    News headline image
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗
     
    Via Benzinga
    Topics Economy
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15
    Via Investor Brand Network
    News headline image
    Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Groundbreaking Ketamine Implant Therapeutic
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Completes Successful Dose-Ranging Study in Advancement of SPC-15
    Via Investor Brand Network
    News headline image
    Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗
     
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Validation of Delivery System for SP-26
    Via Investor Brand Network
    News headline image
    Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology
    Via Investor Brand Network
    News headline image
    Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗
    New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian... 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Positive Results of Alzheimer’s Study
    Via Investor Brand Network
    News headline image
    Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗
    Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD 
    Via Benzinga
    News headline image
    Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗
    Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury 
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Successfully Completes First Phase of Dose-Ranging SPC-15 Study
    Via Investor Brand Network
    News headline image
    Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder ↗
    Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD).  
    Via Benzinga
    News headline image
    Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy ↗
    Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly ad 
    Via Benzinga
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Regulatory Approval for Ketamine Implant, Moves Forward with Partner to Next Stage of Development
    Via Investor Brand Network
    News headline image
    Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
    From Silo Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More ↗
    President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.